All In Biotech

Drug Trial Radar · NCT01760187

Phase I Study of the Safety, Tolerability, PK & PD of Lomitapide in Japanese and Caucasian Subjects With Elevated LDL-C

A Randomized, Double-blind, Placebo-controlled, Single Ascending and Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Lomitapide in Japanese and Caucasian Volunteers With Elevated Low-density-lipoprotein(LDL-C)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

72

Actual

Start

Nov 7, 2012

Primary completion

Jun 3, 2013

Study completion Jun 3, 2013

Sponsor

Lead sponsor
Aegerion Pharmaceuticals, Inc.Industry
Sponsor type
Industry
Collaborators
Richmond Pharmacology Limited
First posted
Jan 4, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study of orally administered lomitapide in healthy male Japanese and Caucasian subjects with elevated LDL-C. The purpose for this study is to evaluate the PK and PD of lomitapide in Japanese subjects as compared to Caucasian subjects.

Conditions

  • Healthy Volunteer

Interventions

  • lomitapideDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax for LomitapideTime frame: 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7
  2. Tmax for LomitapideTime frame: 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7
  3. AUC0-t for LomitapideTime frame: 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7
  4. AUC0-∞ for LomitapideTime frame: 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7
  5. t1/2 for LomitapideTime frame: 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7
  6. Cmax for LomitapideTime frame: 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27
  7. Tmax for LomitapideTime frame: 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27
  8. AUC0-t for LomitapideTime frame: 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27
  9. t1/2 for LomitapideTime frame: 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Richmond Pharmacology Ltd

    Croydon, Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.